Introduction: Ciliated muconodular papillary tumors (CMPTs) are recently characterized, rare peripheral nodules of the lung. These small tumors are histologically comprised of a vaguely organized mixture of nonatypical ciliated columnar cells, mucous cells, and basal cells, and consistently follow a benign clinical course. However, the histogenesis of CMPTs remains uncertain.
Introduction
Ciliated muconodular papillary tumors (CMPTs) are rare peripheral nonendobronchial lung nodules that have recently been characterized. These small nodules are typically located in the peribronchiolar region, and exhibit an overall papillary or glandular architecture. CMPTs consist of a vaguely organized mixture of nonatypical ciliated columnar cells, mucous cells, and basal cells, and are typically enveloped with abundant mucus. Because of the focal stromal destruction and complex architecture-which includes papillary, micropapillary, and focally discontinuous lepidic growths-these lesions may be confused with adenocarcinomas. However, CMPTs consistently follow a benign clinical course, even after limited surgery, and an appropriate differential diagnosis is critical for appropriate patient management. 1 For example, cilia are not usually observed in pulmonary adenocarcinoma, and the presence of cilia and/or terminal plates is one of the most reliable findings to support a benign diagnosis. 2, 3 However, exceptional cases of ciliated adenocarcinoma in the lung have been reported.
The histogenesis of CMPT remains poorly understood. For example, the organized growth pattern and consistent peribronchiolar localization may indicate a metaplastic phenomenon. However, the complex architecture, focal stromal destruction, and autonomous enlargement that have been observed in a few cases indicate a neoplastic quality. Therefore, we undertook next-generation sequencing and high-resolution melting analyses (HRMA) of 10 well-annotated cases of CMPTs to clarify their histogenesis.
Methods

Patients and Clinicopathological Analysis
This study was approved by the institutional review board of the National Cancer Center Hospital (Tokyo, Japan). A total of 10 CMPT cases were identified in our institution between 2006 and 2014. Their clinical and pathological records were retrospectively reviewed, and we performed histological analyses of the resected specimens.
DNA Preparation
We analyzed 10 tumor specimens, including 4 fresh frozen and 6 formalin-fixed, paraffin-embedded (FFPE) tissue samples. Genomic DNA was extracted from the fresh frozen tissues using the QIAamp DNA mini Kit (QIAGEN, Hilden, Germany), and from the FFPE tissues using the QIAamp DNA FFPE Tissue Kit (QIAGEN). DNA was quantified using the Qubit Fluorometer (Life Technologies, Carlsbad, CA).
Target Deep Sequencing of Mutation Hotspots in 50 Cancer-Related Genes
Ten nanograms of DNA were subjected to library preparation for the Ion Ampliseq Cancer Hotspot Panel v2 (Life Technologies), which can detect mutations at 2790 hot spots in 50 cancer-related genes ( Table 1 ). The library DNAs were prepared by amplifying the targeted regions using multiplex polymerase chain reaction (PCR), which was followed by adopter DNA ligation. Concentrations of the library DNA were evaluated via quantitative real-time polymerase chain reaction studies using the Ion Library Quantitation Kit (Life Technologies). Sequencing was performed using the Ion Proton platform (Life Technologies), and mutations were identified using Torrent Suite software (Life Technologies).
Confirmatory Analyses
To confirm the BRAF and EGFR mutations, we performed HRMA (Idaho Technology, Salt Lake City, UT), based on a previously reported method. 5 We also performed immunohistochemistry using a monoclonal antibody to BRAF V600E (1:200 dilution; clone VE1; Spring Bioscience, Pleasanton, CA), and the results were estimated separately for each of the three epithelial components (i.e., ciliated columnar cells, mucous cells, and basal cells). Cytoplasmic staining was considered a positive result.
Results
Clinical Findings
Detailed clinicopathological data for the identical 10 cases have been published separately. 1 All tumors showed semiorganized peribronchiolar growth that consisted of tripartite cellular elements, including ciliated columnar cells, mucous cells, and basal cells (Fig. 1) . None of the patients experienced local recurrence or distant metastasis during a mean follow-up of 43 months (range, 2-88 months).
Target Deep Sequencing of Mutation Hotspots
We conducted next-generation sequencing at a mean depth of Â2237 (range, Â138-12,650) to search for mutations at hotspots in 50 cancer-related genes from ABL1  EGFR  GNA11  KRAS  PTPN11  AKT  ERBB2  GNAQ  MET  RB1  ALK  ERBB4  HNF1A  MLH1  RET  APC  EZH2  HRAS  MPL  SMAD4  ATM  FBXW7  IDH1  NOTCH1  SMARCB1  BRAF  FGFR1  IDH2  NPM1  SMO  CDH1  FGFR2  JAK2  NRAS  SRC  CDKN2A  FGFR3  JAK3  PDGFRA  STK11  CSF1R  FLT3  KDR  PIK3CA  TP53  CTNNB1 GNAS KIT PTEN VHL Table 2 ). The mutated genes consisted of BRAF (50%), EGFR (30%), PTPN11 (20%), CTNNB1 (10%), IDH1 (10%), and TP53 (10%). The mutations in BRAF were two types of missense mutations (V600E in four cases and G606R in one case), and all three EGFR mutations were the same in frame deletion (delE746-T751/S752V). All BRAF and EGFR mutations were validated using HRMA. The BRAF and EGFR mutations were mutually exclusive among the specimens (Fig. 2) .
Immunohistochemistry
In the four cases with the BRAF V600E mutation, all three epithelial components (i.e., ciliated columnar cells, mucous cells, and basal cells) showed similar cytoplasmic staining for BRAF V600E. This finding suggests that all 3 elements were neoplastic components (Fig. 3) . As expected, the BRAF V600E-specific antibody reacted strongly with the cilia of the columnar cells (the internal positive control). 6 
Discussion
In this study, we identified driver gene mutations in most CMPTs, and provided evidence that these enigmatic lesions are indeed neoplastic processes.
Five of the 10 CMPTs (50%) harbored BRAF mutations, including four V600E mutations and one G606R mutation. Mutations in BRAF are a common driver in many different types of benign and malignant tumors in humans 7, 8 ; the most common type is the V600E substitution. BRAF is rarely (3%) mutated in lung adenocarcinomas, and this mutation is even rarer (1.3%) among Asian patients. 9 Therefore, the high incidence of BRAF mutations in CMPTs presents a contrast with the incidence in lung adenocarcinomas. In addition, our histological findings exclude a clear relationship between CMPTs and adenocarcinomas. 1 In addition, BRAFmutated lung adenocarcinomas typically exhibit aggressive features, such as micropapillary, acinar, and solid growth patterns, and CMPT-like morphology has not been documented in our cohort or in a previously reported cohort. 9 Moreover, none of our BRAF mutant CMPTs exhibited worrisome histological findings.
Similarly, the EGFR mutations in three of our CMPTs do not necessarily link these lesions to adenocarcinomas. Although exon 19 deletions (Del-19s) are one of the most common alterations in lung adenocarcinomas, the specific Del-19 that we found in our CMPTs is extremely rare in lung adenocarcinomas. According to the Somatic Mutations in EGFR Database, the most frequent Del-19 in lung adenocarcinomas is delE746-A750 (28.89%), followed by delL747-P753insS (2.49%) and delL747-A750insP (1.73%). 10 However, the EGFR deletion in three of our CMPTs was delE746-T751/S752V, and this deletion is extremely rare in lung adenocarcinomas (only one reported case). 10 In addition, that particular case likely did not involve a CMPT, because cilia were not documented. Therefore, CMPT-like morphology has never been documented in EGFR-mutated cancers, and the presence of mucous cells is rare in EGFR-mutated adenocarcinomas. Moreover, none of the EGFR mutant CMPTs in our cohort exhibited malignant histological findings. 
and PTPN11-E76K (COSM13000)
PTPN11-P491L (COSM13034) and TP53-L289F(COSM45446) It is notable that the presence of driver gene alterations in CMPTs does not dictate their clinical behavior, because gene mutations can be present both in benign and malignant lesions. For example, BRAF mutations have been found in benign lesions, such as melanocytic nevi, Langerhans cell histiocytosis, biliary adenomas, and pilocytic astrocytomas. 11, 12 In addition, the EGFR mutation has been detected in atypical adenomatous hyperplasia. 13 However, none of the reported CMPT cases, including our present series, have metastasized to the local lymph nodes or distant sites, and none recurred after surgery. The benign nature of CMPTs is also implied by the bland cytology, the lack of mitotic figures, and the invariable presence of ciliated and basal cell populations within the tumor. Nevertheless, larger studies with longer follow-ups are necessary to accurately determine the course of CMPTs.
Immunohistochemical analysis with the BRAF V600E-specific antibody revealed that all three epithelial components (i.e., ciliated cells, mucous cells, and basal cells) were equally positive for this antibody. This finding supports the theory that each of these tripartite elements constitutes a neoplastic component, at least in these four CMPTs. This staining also eliminates the remote possibility that florid metaplastic changes obscured the presence of a minute BRAF-mutant adenocarcinoma.
Our discovery of BRAF and EGFR mutations in most of our CMPT cases may also help explain the relationship between rare benign lesions in the lung. For example, several groups of researchers have reported unusual peripheral lung lesions that are histologically similar (if not identical) to CMPTs, using names such as "solitary peripheral ciliated glandular papillomas," "mucinous adenomatous hyperplasia," and "peripheral pulmonary papillary/ glandular neoplasms with ciliated cells." 14, 15 Similarly, the histologic features of mixed papillomas resemble those of CMPTs, 2 although these two tumors can be differentiated by at least their locations (central versus peripheral) and their associations with the bronchial lumens (endobronchial versus nonendobronchial). Therefore, BRAF and EGFR mutational assays in these benign tumors may clarify their nosological relationship with CMPTs.
In conclusion, we have identified frequent driver mutations of BRAF or EGFR in most of our 10 CMPT cases. These data support the notion that these lesions are neoplastic rather than reactive or metaplastic. 
